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CROSS-PROTECTION MECHANISMS OF INFLUENZA VIRUS VACCINES

by

YU-JIN KIM

Under the Direction of Sang-Moo Kang, PhD

ABSTRACT
Since current influenza vaccine strategy is effective in conferring protection against
vaccine strain-matched influenza viruses but not against antigenically different viruses, the
development of broad cross-protective vaccines is of a high priority to improve vaccination
efficacy and to prevent future pandemic outbreaks. In this study, I investigated the cross-protective
efficacy and the immune mechanism of three different target antigens including hemagglutinin
(HA) based inactivated virus vaccines, neuraminidase (NA) protein vaccines, and tandem repeat
extracellular domains of the ion channel protein M2 (M2e5x) on virus-like particle (M2e5x VLP)
vaccines. Anti-NA antibodies could confer better cross-protection against multiple heterologous
influenza viruses correlating with NA inhibition activity compared to anti-HA antibodies. Whereas
anti-HA antibodies were superior to NA in conferring homologous protection. Anti-NA and M2e
antibodies showed comparable survival protection. To better understand cross-protective vaccine
efficacy, M2e and HA vaccines were tested in different genetic backgrounds. BALB/c mice

showed higher IgG responses and cross-protection than C57BL/6 mice after M2e vaccine
immunization. M2e vaccine immune mice after primary challenges developed strong immunity to
a secondary heterosubtypic virus as a future pandemic.
The classical complement pathway is activated to eliminate antigen-antibody immune
complexes, subsequently followed by complement-dependent cytotoxicity in addition to Fc
receptor-mediated antibody-dependent cell-mediated cytotoxicity. However, the role of
complement system remains largely unknown in influenza virus M2e-mediated cross protective
immunity. This study demonstrated that complement protein C3 is essential in inducing immune
responses to influenza M2e5x VLP vaccination and influenza virus infection, which include M2especific isotype-switched antibody production and M2e-specific effector CD4 and CD8 T cell
responses. C3 deficient (KO) mice showed lower levels of M2e-specific IgG isotype antibodies
after M2e5x VLP vaccination, no control of lung viral replication, and severe weight loss upon
challenge infection compared to those in wild type (WT) mice. Whereas, C3 KO mice were
protected against homologous virus after immunization with hemagglutinin-based virus vaccine
despite lower levels of neutralizing antibodies than those in WT mice. In addition, C3 KO mice
showed impaired recruitment of macrophages and different subsets of dendritic cells. The findings
in this study suggest that C3 is a key regulator in developing protective immunity by nonneutralizing antibody-based vaccination.
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1
1.1

INTRODUCTION

Influenza virus
Influenza virus contains eight segmented negative-sense RNA genomes and belongs to the

family Orthomyxoviridae. Influenza A viruses are divided into different subtypes based on
hemagglutinin (HA) and neuraminidase (NA) proteins on the surface of the virus.1 At present,
antigenically different influenza viruses with one combination out of 18 HA (H1-H18) and 11 NA
(N1-N11) subtype molecules are known to exist and continue to mutate in diverse hosts including
humans, birds, and pigs.1,2 In addition to the high mutation rates of HA and NA, segmented
structures of their genome facilitate genetic reassortment when the host is infected with more than
one strain of influenza A viruses.3 This unique feature of influenza viruses has been considered as
one of the main reasons for the emergence of novel virus strains which are more likely to cause
pandemics in humans.4
Current influenza vaccination is based on immunity to highly changeable HA and confers
protection limitedly against homologous virus infection so that annual updates of influenza
vaccines are required to match the antigenicity of the virus strains which are predicted to circulate.5
Moreover, this strategy is not effective in preventing the pandemic outbreaks, raising the need for
developing broadly cross-protective influenza vaccines.6

1.2

Target antigens for cross-protective influenza vaccines
Among the eleven influenza viral proteins, three proteins HA, NA, and M2 are expressed on

the surface of virions. Therefore, these 3 surface proteins were evaluated and compared as the
target antigens for cross-protective influenza vaccines in this study. The features and immune
responses induced by each antigen are discussed below.

2

1.2.1

HA
HA is the most dominant homotrimeric viral surface hemagglutinin glycoprotein which

mediates the attachment of the influenza virions to host cells. It binds to sialic acids on glycan
structures of hosts’ cellular receptors. After binding to the receptors, HA leads to the fusion
between viral and cellular endosomal membranes, causing the release of the viral genome into the
cytoplasm.7 Immunization with HA vaccines (whole inactivated virus, inactivated split virus
vaccine, live attenuated influenza virus vaccine) primarily induces immunity to the globular head
domain of HA which is surrounded by highly variable antigenic regions so that the immune
responses are strain-specific to the influenza viruses.5 It has been known that broadly neutralizing
monoclonal antibodies which are specific for the highly conserved HA stem region can be induced
in mice and humans8-10 in a lower frequency than the globular head domain strain-specific
antibodies.11 The HA stem region is less immunogenic than the globular head domain. One
possible reason is that the globular head physically masks the stem region on the influenza virion.
Another reason can be the close proximity of the HA stem region to the viral membrane so that
hosts’ immune cells hardly recognize it.12

1.2.2

NA
NA is a homotetrameric viral surface glycoprotein which has the sialidase activity.13 It is

required to transport the influenza virions through mucosal surfaces and to release of budding virus
particles from the host cell surface.1 Epidemiologic studies indicated that anti-NA immunity and
NA inhibitors such as zanamivir, oseltamivir, or peramivir prevent severe disease or death by
influenza viral infection.14 NA targeting antibodies do not have virus neutralizing activity,
providing infection-permissive protection.15 Studies have demonstrated that NA immunity induces

3

a broad spectrum of cross protection within the same subtype.16,17 Nonetheless, contribution of NA
antibodies to cross protection is not well understood yet in comparison with other viral surface
antigens.

1.2.3

M2e
M2 is an integral membrane protein, which has the pH-dependent proton channel activity,

and required for HA maturation and viral genome release into the cytoplasm.12 After influenza
virus enters into the host cells, M2 decreases the pH of the virus interior by opening the proton
channel across the viral membrane. Membrane fusion between the virus and the host cell is
facilitated in the low pH condition.5 The extracellular domain of M2 (M2e) has been considered
as one of the promising antigens for cross-protective influenza vaccines. One main reason is that
passive administration of anti-M2e antibodies can reduce viral replication and pathological
symptoms in mice without viral neutralizing activity.18 Another reason is that the sequence of M2e
is highly conserved (~ 99%) among human influenza A viruses.19,20 However, M2 itself is a poor
immunogen. To enhance immune responses, M2e vaccines have been reported using a variety of
carrier vehicles such as hepatitis B virus core particles21,22, human papillomavirus L proteins23,
phage Q β -derived protein cores24, keyhole limpet hemocyanin25, bacterial outer membrane
complexes26, liposomes27, cholera toxin subunit28, and flagellin29. Also, different adjuvants were
used in the M2e vaccines, which include Freund’s adjuvant30, monophosphoryl lipid A27,28, cholera
toxin subunits31,32, and heat-labile endotoxin22,33. In addition, virus-like particle (VLP) vaccines
presenting heterologous tandem repeat M2e (M2e5x VLP) were effective in inducing cross
protection against different subtypes of influenza viruses in the absence of adjuvants.34

4

1.3

Possible mechanisms of cross-protective influenza vaccines
Since cross-protective antibodies do not have virus neutralizing activity, those antibody-

mediated immune protection has been considered to be connected with antibody-dependent cell
cytotoxicity (ADCC) or complement-mediated lysis.35-38 Innate immune cells such as
macrophages, dendritic cells, neutrophils, and NK cells lead to lyse antibody-bound infected cells
via interaction between Fc receptors (FcR) on their surface and antigens on the infected cells.13,39,40
Based on these findings, FcR-mediated ADCC can be a possible mechanism of the cross-protective
immunity. Complement-mediated cell lysis is also a key mechanism for virus elimination.41,42 In
the case of M2e-mediated immunity, it is still controversial whether the complement system is
required for protection.35,38 In addition, several studies have shown that M2e-specific T cells play
a role in enhancing cross protection against influenza infection.28,43,44
Cross protective immune mechanisms induced by NA are rarely known. However, NA
contains two highly conserved sequences and even one of them shows 100% conservation across
all influenza A and B viruses.45 This fact suggests that NA can be a promising target for universal
influenza vaccines. Indeed, there have been a few reports that NA immunity can confer cross
protection to a certain extent.16,17,46 However, further studies are still needed to understand detailed
working mechanisms of NA-mediated immunity.

1.4

The role of the complement system in the regulation of adaptive immune responses.
Complement is well known as a primitive surveillance system which is a key for the clearance

of infected pathogens during inflammation responses.47,48 Moreover, the complement system
regulates both humoral and T cell immunity.49 The complement system is involved in the B cell
responses via complement receptors CD21 and CD3550, and by localizing antigens to follicular
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dendritic cells (FDCs), which are specialized cells secreting chemoattractant chemokines for B
lymphocytes51. Although the mechanism is still unclear, complement C3 protein was reported to
be important for inducing CD4 and CD8 T cell responses to influenza virus infection.52

2
2.1

EXPERIMENTAL METHODS

Animals and reagents
A/California/04/2009

(A/Cal)

H1N1,

A/Puerto

Rico/8/1934

(A/PR8)

H1N1,

A/Philippines/2/1982 (A/Phil) H3N2, A/Wisconsin/67/2005 (A/Wis) H3N2, and reassortant
A/Vietnam H5N1 (rgH5N1) containing H5 HA with removed polybasic residues and NA from
H5N1 A/Vietnam/1203/2004 and six internal genes from A/PR8 H1N1 were propagated in
embryonated hen’s eggs as previously described.53,54 Inactivated virus vaccines (A/PR8, A/Phil)
were prepared by treating the virus with formalin at a final concentration of 1:4000 (v/v) as
previously described.55 M2e5x VLP containing tandem repeat of heterologous M2e derived from
human (2xM2e), swine (1x), and avian (2xM2e) influenza virus was prepared as detailed in
previous study.34 H5 VLP presenting H5 type of HA protein from A/Indonesia/05/2005 was
previously described.54 Briefly, Sf9 insect cells were co-infected with recombinant baculoviruses
expressing influenza M1 matrix core protein and M2e5x or H5 HA. M2e5x VLP and H5 VLP
vaccines were purified from cell culture supernatants containing released VLP by sucrose gradient
ultracentrifugation and characterized as reported.34,54 N1 NA protein derived from A/Cal (NR19234) and N2 NA protein derived from A/Wis (NR-19237) were provided from BEI resources.
Commercial human influenza split A/Cal vaccine was obtained from a vaccine manufacturing
company (Green Flu-S; Green Cross, South Korea).
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2.2

Immunization and challenge
Adult wild type and mutant mice (6-10 weeks old) used in this study include BALB/c,

C57BL/6, CD4KO (B6.129S2-Cd4tm1Mak/J), CD8KO mice (B6.129S2-Cd8atm1Mak/J), and C3KO
(B6.129S4-C3tm1Crr/J) and were obtained from the Jackson Laboratory (Sacramento, CA). FcRgdeficient mice (FcRg-/- encoded by Fcer1g on the BALB/c genetic background) were purchased
from Taconic Farms (Hudson, NY). Groups of each strain of mice (n=5 or 10, males and females)
were intramuscularly (i.m.) immunized with 10 µg (total proteins) of M2e5x VLP, H5 VLP (H5
HA from A/Vietnam/1203/2004), H3N2i (whole inactivated A/Philippines/2/1982 virus), 5 µg of
N1 or N2 NA protein with adjuvant MF59 (1:1 vol), or 1 µg of split vaccines derived from A/Cal
H1N1 or A/PR8 H1N1 by prime – boost regimen at a 3-week interval. At 4 weeks after boost
immunization, immunized mice were then challenged intranasally with a sublethal dose of
A/Philippines/2/1982 H3N2 (0.8 X LD50) or rgH5N1 (0.8 X LD50), or a lethal dose of A/Cal H1N1
(17 X LD50) or A/Phil H3N2 (10 X LD50). For secondary challenge, mice survived from primary
infection were challenged with a lethal dose of A/California/04/2009 H1N1 (10 X LD50) at 7 weeks
after the primary infection. Survival rate and body weight loss were daily monitored for 14 days
upon infection. All animal experimental procedures in this study were approved by the Georgia
State University Institutional Animal Care and Use Committee review boards.

2.3

Determination of antibody responses
Influenza virus-specific or M2e-specific antibody levels were determined by enzyme-linked

immunosorbent assay (ELISA). Immune sera were serially diluted and then applied to the 96 well
plate (Corning Incorporated, Tewksbury, MA) that were coated with M2e peptide, inactivated
A/California H1N1, A/PR8 H1N1, A/Philippines H3N2, A/Wisconsin H3N2, A/Indonesia
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rgH5N1, or A/Vietnam rgH5N1 virus as previously described.56,57 IgG and IgG isotype levels were
determined by HRP conjugated anti-mouse IgG, IgG1, IgG2a, IgG2b, or IgG2c (SouthernBiotech,
Birmingham, AL) and tetramethylbenzidine (eBioscience, San Diego, CA) as a substrate.58

2.4

Lung virus titers
Lung samples were collected from the groups of mice at 7 days after challenge. Viral titers

were determined as described previously.34 Briefly, lung extracts were serially diluted in 10-fold
and injected into 10 days old embryonated chicken eggs. The 50% of egg infectious dose (EID50)
was calculated by the Reed-Muench method.

2.5

Hemagglutination inhibition assay
Hemagglutination inhibition (HI) assay was performed as previously described.59 Immune sera

were mixed with receptor destroying enzyme (Sigma Aldrich, St. Louis, MO) and then incubated
at 37 °C. At 16 hours after incubation, samples were heat inactivated at 56 °C for 30 min. Serially
2-fold diluted sera were incubated with 8 HA units of A/California H1N1, A/PR8 H1N1,
A/Philippines H3N2, or rgH5N1 for 30 min, followed by adding 0.5% chicken red blood cells
(Lampire Biological Laboratories, Pipersville, PA) to determine HI titers.

2.6

Neuraminidase inhibition assay
The optimal concentrations of viruses for the subsequent Neuraminidase inhibition (NI) assays

were determined based on the NA activity of each virus. NI activity of immune sera was measured
using fetuin-based assay procedure as described.16 Briefly, 96-well plates were coated with fetuin
(50 µg/ml) (Sigma Aldrich, St. Louis, MO) and incubated overnight at 4 °C. After washing, plates
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were blocked with PBS containing 1% BSA for 1 hour. 2-fold serially diluted immune sera were
incubated with an equal volume of virus for 1.5 hours and then added to the fetuin-coated plates
and incubated for 2 hours at 37 °C. Peroxidase-labeled peanut agglutinin (2.5 µg/ml) (Sigma
Aldrich, St. Louis, MO) was added to each well and incubated for 2 hours. The NA activity levels
were determined by using tetramethylbenzidine (eBioscience, San Diego, CA) as a substrate. OD
values were read at 490nm.

2.7

Cytokine ELISPOT
To detect interferon (IFN)-γ and interleukin (IL)-4 spot forming cells (SFCs), splenocytes

(5×105 cells/well) and lung cells (2×105 cells/well) were cultured on 96 well plates coated with
anti-mouse IFN-γ or IL-4 monoclonal antibodies (BD Biosciences, San Diego, CA) in the presence
of M2e peptide (4 µg/ml). The cytokine spots were developed with biotinylated mouse IFN-γ, IL4 antibodies and alkaline phosphatase labeled streptavidin (BD Pharmingen, San Diego, CA). The
spots were visualized with a 3,3’-diaminobenzidine substrate and counted by an ELISpot reader
(BioSys, Miami, FL).

2.8

In vivo protection assay of immune sera
To test whether M2e5x VLP immune sera contribute to cross protection, in vivo protection

assay was performed as described previously.34 Briefly, heat inactivated sera at 56 °C for 30 min
were diluted and mixed with a lethal dose (10 X LD50) of A/California H1N1, rgH5N1, or
A/Philippines H3N2. Naïve mice were intranasally infected with a mixture (50 µl) of virus and
sera, and the survival rates and body weight changes were daily monitored for 14 days.
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2.9

Intracellular cytokine staining and flow cytometry assay
For intracellular cytokine analysis, harvested cells were stimulated with M2e peptides and then

stained with fluorescence-labeled anti-mouse CD4 and anti-mouse CD8 antibodies. Subsequently,
the cells were made permeable by using the Cytofix/Citoperm kit (BD Biosciences, San Diego,
CA) and intracellular cytokines were stained with anti-mouse IFNg and anti-mouse Granzyme B
antibodies. All antibodies were purchased from eBioscience. Stained cells were analyzed using
LSR Fortessa (BD Biosciences, San Diego, CA) and FlowJo software (Tree Star).

2.10 Germinal center B cell staining and flow cytometry assay
To determine the germinal center B cell phenotype, cells were harvested from mediastinal
lymph nodes (MLN) and then stained with fluorescence-labeled anti-mouse B220, GL7, IgD, and
CD19 antibodies. All antibodies were purchased from eBioscience. Stained cells were analyzed
using LSR Fortessa (BD Biosciences, San Diego, CA) and FlowJo software (Tree Star).

2.11 Intraperitoneal cell phenotypes
Peritoneal exudates were harvested from WT and C3 KO mice (n=5 each). Isolated peritoneal
cells were treated with Fc receptor blocker (anti-CD16/32) and then stained with fluorescence
labeled antibodies; CD11b (clone M1/70), CD11c (clone N418), F4/80 (clone BM8), major
histocompatibility complex class II (MHC-II) (clone M5/114.15.2), Ly6c (clone HK1.4), and
B220 (clone RA3-6B2). All antibodies were purchased from eBioscience. Stained cells were
analyzed using LSR Fortessa (BD Biosciences, San Diego, CA) and FlowJo software (Tree Star).
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2.12 Statistical analysis
All results are expressed as the mean ± standard error of the mean (SEM). Significant
differences among treatments were evaluated by 2-way ANOVA. P-values of less than or equal to
0.05 were considered statistically significant.
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3

CHAPTER 1. ROLES OF ANTIBODIES TO INFLUENZA A VIRUS

HEMAGGLUTININ, NEURAMINIDASE, AND M2E IN CONFERRING CROSS
PROTECTION

3.1

Summary
Although neuraminidase (NA) is the second major viral glycoprotein of influenza virus, its

immune mechanism as a vaccine target has been less considered. Here we compared the properties
of antibodies and the efficacy of cross protection by N1 and N2 NA proteins, inactivated split
influenza vaccines (split), and tandem repeat extracellular domain M2 on virus-like particles
(M2e5x VLP). Anti-NA immune sera could confer better cross-protection against multiple
heterologous influenza viruses correlating with NA inhibition activity compared to split vaccine
immune sera. Whereas split vaccine was superior to NA in conferring homologous protection. NA
and M2e immune sera each showed comparable survival protection. Protective efficacy by NA
immune sera was lower in Fc receptor common γ-chain deficient mice but comparable in C3
complement deficient mice compared to that in wild type mice, suggesting a role of Fc receptor in
NA immunity.

13

3.2

3.2.1

Results

NA protein vaccination induces IgG antibodies cross-reactive to heterologous virus.
We compared the relative contributions and roles of serum antibodies specific for NA,

inactivated split influenza vaccine (HA), and M2e in conferring cross protection. The groups of
mice were intramuscularly immunized with N1 NA protein (5 µg, A/Cal H1N1), N2 NA protein
(5 µg, A/Wis H3N2), M2e5x VLP (10 µg), inactivated split influenza vaccines (1 µg, A/PR8 H1N1
or A/Cal H1N1). Reactivity of IgG antibodies in immune sera to different strains of influenza virus
was compared among the groups at 2 weeks after boost immunization (Fig. 3.1). N1 NA protein
immune sera showed reactivity to the homologous A/Cal H1N1 and heterologous rgH5N1 and
A/PR8 H1N1 viruses. A similar pattern was also observed with N2 NA protein immune sera at
lower levels of IgG antibodies that bind to homologous A/Wis H3N2 virus and heterologous
A/Phil H3N2 virus. However, both N1 and N2 immune sera did not show significant reactivity to
different subtypes of influenza virus. M2e5x VLP immune sera exhibited high levels of IgG
antibodies reactive to M2e peptide antigens (Fig. 3.1F). A/Cal split vaccine developed more crossreactive IgG antibodies than A/PR8 split vaccine (Fig. 3.1B, C) although both showed high IgG
antibodies specific for homologous virus. Overall, IgG antibodies induced by A/Cal split vaccines
were cross-reactive to heterosubtypic influenza viruses but not to M2e. NA protein-induced IgG
antibodies could bind to homologous and heterologous viruses within the same NA subtype.
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Figure 3.1 Reactivity of vaccine-specific antibodies to different strains of influenza viruses.
Figure 1. Reactivity of antibodies to different strains of influenza viruses
Immune sera were collected after boost immunization of BLAB/c mice (n= 5 per group) with N1 NA protein (A/Cal
H1N1), N2 NA protein (A/Wis H3N2), M2e5x VLP, split vaccine (A/PR8 H1N1, A/Cal H1N1), or whole A/Phil
H3N2 virus. Whole inactivated virus particles and M2e peptide were used as ELISA coating antigens: (A) A/Cal
H1N1, (B) rgH5N1, (C) A/PR8 H1N1, (D) A/Wis H3N2, (E) A/Phil H3N2 or (F) M2e peptide. Sera were pooled and
serially diluted.

3.2.2

NA protein vaccination develops NA-inhibiting cross-reactive antibodies.
As a measure of functional antibodies, NA inhibition (NI) activity of immune sera was

determined by a fetuin-based assay (Fig. 3.2). A/Cal N1 NA protein-induced antibodies exhibited
significantly higher levels of NI activity against homologous virus than split vaccine immune sera
(Fig. 3.2A). Also, A/Cal N1 NA immune sera showed low levels of NI activity against
heterologous rgH5N1 and heterosubtypic A/Phil H3N2 virus (Fig. 3.2B & D). N2 NA immune
sera displayed significant levels of NI activity against the homologous virus A/Wis H3N2 and
heterologous A/Phil H3N2 virus (Fig. 3.2C & D). Split A/Cal vaccine immune sera show low NI
activity against homologous but not heterologous virus. Inactivated split influenza vaccines raise
high hemagglutination inhibition titers in a strain specific manner as expected (Fig. 3.2E). These
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results indicate that NA protein vaccination induces higher NI activity against both homologous
and heterologous viruses than current vaccine platforms of inactivated influenza split virus. NI
activity was low or hardly detected in split vaccine immunized mice.
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Figure 3.2 NA inhibition activity of vaccine-specific antibodies to different strains of influenza viruses.
Immune sera were collected and pooled after immunization (n=5) with N1 NA (A/Cal), N2 NA (A/Wis), M2e5x
VLP, split vaccine (A/PR8, A/Cal), or inactivated A/Phil H3N2 virus. NA inhibition assays were performed against
different strains of influenza viruses: (A) A/Cal H1N1, (B) rgH5N1, (C) A/Wis H3N2, or (D) A/Phil H3N2. (E) HI
titers against A/Cal H1N1, A/PR8 H1N1, rgH5N1, and A/Phil H3N2 were determined from immune sera of split
vaccines (A/PR8 H1N1 and A/Cal H1N1).
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3.2.3

NA protein vaccination is less effective in homologous protection than inactivated split
and in heterologous protection compared to M2e5x VLP.
We investigated protective efficacy in actively vaccinated mice after challenge. As

described for Figure 1, mice were immunized with N1 (A/Cal) or N2 (A/Wis) NA proteins, split
vaccine (A/Cal), or M2e5x VLP. Immune mice with A/Cal split vaccine developed significant
levels of virus-specific serum IgG antibodies (Fig. 3.3A) and they showed high HI activity against
the homologous virus strain (Fig. 3.3B). Mice immunized with A/Cal split vaccine did not show
body weight loss after challenge with homologous A/Cal H1N1 virus (Fig. 3.3C). Mice that were
immunized with A/Cal N1 NA protein displayed significant weight loss (~18%), but all mice in
this group survived after challenge whereas all naïve mice died of infection (Fig. 3.3C). Regarding
A/Wis N2 NA immunization, a homologous virus challenge mouse model is not available. Thus,
we determined efficacy of N2 NA vaccination after a sub-lethal dose challenge with heterologous
virus A/Phil H3N2 in comparison with M2e5x VLP vaccination. The A/Wis N2 NA group
exhibited lower levels of weight loss (~15%) and a quicker recovery compared to the naïve control
(~21%) after A/Phil virus challenge (Fig. 3.3D). Interestingly the mice immunized with M2e5x
VLP, a representative cross-protective vaccine, showed better cross protection (~5% weight loss)
against A/Phil H3N2 virus than N2 NA protein immunized mice (Fig. 3.3D). Overall, these results
suggest that NA protein alone is less effective as a vaccine candidate in homologous protection
than HA-based split vaccine and in cross protection compared to M2e5x VLP experimental
vaccine.

17

A

B

Cal H1N1i - IgG

A/California H1N1
8

Split (Cal H1N1) Boost
1.0

Split (Cal H1N1) Prime

0.5

HI titer (log 2)

**

6
4
2

ve
ai

1N
H
al

pr
Sp

lit

N

(C

1

Sera Dilution

N

x10,000 x100,000

n

x1,000

ot

x100

1)

0

0.0

ei

OD (450 nm)

1.5

120

Body weight (%)

D

A/California H1N1
N1 protein

110

Split (Cal H1N1)

100

Naive

90
80
70

0 1 2 3 4 5 6 7 8 9 1011121314

Days post infection

A/Philippines H3N2
120

Body weight (%)

C

N2 protein

110

M2e5x VLP

100

Naive

90
80
70

0 1 2 3 4 5 6 7 8 9 1011121314

Days post infection

Figure
Vaccination with
proteins
is less
effective
split vaccine
or M2e5x VLP in inducing homologous and
Figure
3.33.Vaccination
withNA
NA
proteins
induces
lessthan
effective
protection.
heterologous
protection.
Mice were prime-boost immunized with N1 (A/Cal) or N2 (A/Wis) NA proteins (5µg), M2e5x VLP (10µg), or A/Cal
split vaccine (1µg). (A) Prime and boost IgG levels of A/Cal split vaccine immunized mice. (B) HI titers against A/Cal
H1N1 with immune sera of N1 NA protein and split vaccine (A/Cal H1N1). At 4 weeks after boost immunization,
mice were challenged with a lethal dose of influenza virus and monitored for body weights. (C) N1 NA protein and
split vaccine immunized mice were challenged with a homologous A/Cal virus. (D) N2 NA protein (A/Wis H3N2)
and M2e5x VLP immunized groups were challenged with a heterologous virus (A/Phil H3N2). Data represent the
mean ± SEM. Statistical significances were evaluated by 2-way ANOVA. **p<0.01.

3.2.4

NA protein immune sera confer better cross protection against heterologous strains.
We determined the roles of different vaccine immune sera in conferring cross-protection.

Naïve mice were infected with a mixture of influenza virus and immune sera collected from each
vaccine group, and then daily monitored for weight changes and survival rates for 14 days (Fig.
3.4 A-C). Naïve sera did not confer protection against A/Cal H1N1, rgH5N1, and A/Phil H3N2
viruses as evidenced by severe weight loss (>20%) or no survival rates (Fig. 3.4 A-C). In contrast,
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N1 protein immune sera conferred protection against homologous A/Cal H1N1 virus and
heterologous rgH5N1 virus although low to moderate weight loss of 5-10% was observed (Fig.
3.4 A, B). A/Cal split vaccine immune sera did not provide cross protection against rgH5N1 virus
as shown by severe weight loss similar to that in naïve control sera (Fig. 3.4B). In an additional
set of comparing cross protection against A/Phil H3N2 virus, the mice with N2 protein (A/Wis)
immune sera showed weight loss of 16% similar to M2e5x VLP immune sera but better protection
with a quicker recovery than A/PR8 split vaccine sera exhibiting severe weight loss (~25%) (Fig.
3.4C). Interestingly, combination of M2e5x VLP and N2 NA immune sera resulted in synergistic
effects on improving protection against A/Phil virus in naïve mice (Fig. 3.4C). Taken together,
these results suggest that NA targeting antibodies confer better cross protection compared to split
vaccine-induced antibodies.

3.2.5

Fc receptor plays a role in NA antibody-mediated protection but C3 is not required.

We tested whether Fc receptors are involved in NA antibody-mediated protection. Naïve wild
type (BALB/c) and Fc receptor common γ-chain knock-out (FcR KO) mice were infected with a
mixture of A/Cal H1N1 virus and N1 protein-immune sera (Fig. 3.4D). BALB/c mice showed
minimal or no weight loss and were well protected against homologous A/Cal H1N1 virus.
However, FcR KO mice that were inoculated with A/Cal H1N1 virus and N1 NA immune sera
resulted in substantial weight loss (~12%), but they were still protected compared to the FcR KO
mice with naïve serum plus virus inoculation (Fig. 3.4D). These results suggest that Fc receptor
contributes to the protection mediated by NA antibodies.
To test whether the complement system plays a role in NA-mediated protection, naïve wild
type (C57BL/6) and C3 knock-out (C3 KO) mice were infected with a mixture of A/Cal H1N1
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virus and N1 protein-immune sera (Fig. 3.4E). No significant difference in protective efficacy was
observed between wild type and C3 KO mice. Both wild type and C3 KO mice that received N1
immune sera and virus exhibited a delay and moderate levels in weight loss (12-15%), compared
to naïve serum control groups displaying severe (20-25%) weight loss. It is noted that the C3 KO
mice with naïve sera and virus could not fully recover weight loss. C57BL/6 mice showed a trend
of lower efficacies in conferring protection than those in BALB/c mice.
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Figure 4. Efficacy of the antibody-mediated protection

Figure 3.4 Roles of immune sera in conferring protection in naïve mice.
Immune sera were collected and pooled after immunization of BALB/c mice (n=5) with N1 NA (A/Cal), N2 NA
(A/Wis), split vaccine (A/Cal or A/PR8 H1N1), M2e5x VLP, or a mixture of N2 NA and M2e5x VLP. Naïve BALB/c
mice were intranasally infected with a lethal dose of influenza virus mixed with immune or naïve sera, and monitored
for weight changes. Multiple strains of viruses were tested: (A) A/Cal H1N1, (B) rgH5N1 and (C) A/Phil H3N2. (D)
BALB/c and Fc receptor knock-out (FcR KO) or (E) C57BL/6 and C3 knock-out (C3 KO) mice (n=4 per each group)
were intranasally infected with a lethal dose of influenza virus (A/ Cal) mixed with immune or naïve sera. Data
represent the mean ± SEM. Statistical significances were evaluated by 2-way ANOVA. ****p<0.0001.
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3.3

Discussion
This study compared the efficacy of three different influenza vaccine antigens by using each

representative vaccine: split vaccines for HA immunity, NA proteins for NA immunity, and M2e5x
VLP for M2e immunity. We evaluated the protective efficacy of each antigen-specific immune
sera by determining: (1) their reactivity to different subtypes of influenza A viruses, (2) enzyme
inhibition activities to HA and NA, and (3) protection by active immunization or passively
administrated antibodies. We found that antibodies to NA proteins confer a broader range of cross
protection than HA antibodies. In addition, protection by NA-specific antibodies appears to be
mediated by NA inhibition activity and Fc receptors.
Virus neutralizing activity by HA-targeting antibodies is the most effective in conferring
protection against the homologous influenza virus. Immunization with split vaccines (A/Cal
H1N1, A/PR8 H1N1, A/Phil H3N2) induced significant levels of antibodies binding to
heterologous influenza viruses. Nonetheless, these split vaccine immune sera did not show HI
activity against heterosubtypic strains and failed to induce cross protection against viral infection
with different subtypes, limiting the protection to homologous virus. Based on these results, split
vaccines tend to induce mainly HA immunity to homologous virus. NA protein immunization
raised antibodies that are cross reactive to different influenza virus strains within the same NA
type. In a similar pattern, NA protein immune sera showed high levels of NI activity to homologous
and heterologous virus strains. In contrast to HA immunity by split vaccines, NA antibodies
contribute to survival protection against homologous and heterologous influenza virus within the
same NA subtype viruses, which is consistent with a previous study.17,60
HA targeting vaccines are superior to NA vaccines in homologous protection. This is because
HI activity of anti-HA antibodies can lead to sterilizing immunity, which cannot be comparable to
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infection permissive cross protection. Active immunization with NA protein vaccines induced
survival protection against heterologous virus challenge, but its protective efficacy was lower than
that of M2e5x VLP which we previously described as for a cross protective vaccine candidate.61
It is unclear what differences are in the protective mechanisms between NA protein and M2e5x
VLP vaccines. T cells induced by M2e5x VLP vaccination were shown to play a role in conferring
cross protection.43 It is possible that in addition to M2e antibodies, T cells induced by M2e5x VLP
vaccination contribute to more effective cross protection than NA protein immunization since we
observed that N2 NA protein and M2e5x VLP immune sera conferred a similar level of protection
against A/Phil H3N2 virus. We hypothesized that non-neutralizing antibody-mediated
mechanisms would be involved in the NA antibody-mediated protection, which include antibodydependent cellular cytotoxicity (ADCC) and complement-dependent cytolysis (CDC). Fc receptor
is known to be required for ADCC via phagocytic cells such as macrophages, natural killer (NK)
cells, and neutrophils.62 C3 component is an essential factor in the complement pathway leading
to clearance of antigen-antibody immune complexes via CDC.6 N1 type NA protein immune sera
conferred protection against homologous viral infection in wild type (BALB/c) mice without
displaying weight loss whereas a moderate level of body weight loss was observed in FcR KO
mice. These results suggest that Fc receptors partially contribute to the protection by NA
antibodies. In line with the roles of Fc receptors in mediating protection, HA stalk-specific
antibodies were shown to induce phagocytosis of immune complexes in a FcR dependent
manner.63,64 Similarly, Fc receptors were required for M2e immune mediated protection.57 In
contrast, a similar pattern of weight loss was observed in both wild type (C57BL/6) and C3 KO
mice, which indicates that C3 is not required for protection by NA antibodies. Significantly more
weight loss in C57BL/6 mice than in BALB/c mice might be due to different genetic backgrounds
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in these two strains of mice. C57BL/6 mice showed a defect in developing granzyme B-secreting
CD8 T cells after influenza virus infection compared to BALB/c mice (unpublished data). It has
been reported that C57BL/6 strain is more susceptible to influenza virus infection than BALB/c
strain.65
To overcome limitations of a single vaccine antigen in conferring cross protection, a
multicomponent vaccine strategy was reported. Supplementation of inactivated influenza vaccines
with M2e-based antigens resulted in inducing significantly improved cross protection in BALB/c
mice.43 It was reported that addition of NA and M2e vaccines to recombinant HA vaccines confers
long-lasting cross protection against primary and secondary influenza virus infections in BALB/c
mice.66 We found that combination of N2 NA and M2e5x VLP immune sera resulted in conferring
synergistically improved cross protection compared to each immune serum alone. Our unpublished
data support the benefits of multicomponent vaccination that the combination of split, NA protein,
and M2e5x VLP vaccines induced antibodies specific to each vaccine antigen, providing
significantly improved cross protection in C57BL/6 mice than single component vaccines (data
not shown). In addition, we found that the efficacy of cross protection by multicomponent vaccines
was significantly lower in either CD4 or CD8 T cell deficient mice compared to that in wild type
C57BL/6 mice, suggesting important roles of CD4 and CD8 T cells in cross protection (data not
shown). Taken together, findings in this study highlight different roles of HA, NA, and M2e as
vaccine antigens and suggest a new possible strategy for improving cross protection.
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3.4

Conclusion
This study directly compared the protective efficacy and the properties of antibodies induced

by different representative vaccine antigens, which are Hemagglutinin (HA), NA, and the
extracellular domain of M2 (M2e). Anti-NA antibodies induced effective protection against
multiple heterologous Influenza viruses. These protective immune responses are established by
NA inhibition activity of anti-NA antibodies and Fc receptor-mediated antibody-dependent
cellular cytotoxicity (ADCC). In contrast, HA immunity showed only strain-specific protection
that are mediated by HA inhibition activity of anti-HA antibodies even though anti-HA antibodies
were able to bind to heterosubtypic viruses. Taken together, this study suggests a possible vaccine
strategy and its immune mechanism that conventional HA-targeting vaccines are supplemented
with NA and M2e-targeting vaccines to take advantages from different vaccine targets.
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4

CHAPTER 2. CROSS PROTECTIVE EFFICACY OF INFLUENZA VIRUS M2E
CONTAINING VIRUS-LIKE PARTICLES IS SUPERIOR TO HEMAGGLUTININ
VACCINES AND VARIES DEPENDING ON THE GENETIC BACKGROUNDS OF
MICE.

4.1

Summary
Influenza virus M2 extracellular domain (M2e) has been a target for developing cross

protective vaccines. However, the efficacy and immune correlates of M2e vaccination are poorly
understood in the different host genetic backgrounds in comparison with influenza vaccines. We
previously reported the cross protective efficacy of virus-like particle (M2e5x VLP) vaccines
containing heterologous tandem M2e repeats (M2e5x) derived from human, swine, and avian
influenza viruses. In this study to gain better understanding of cross protective influenza vaccines,
we compared immunogenicity and efficacy of M2e5x VLP, H5 hemagglutinin VLP (H5 VLP),
and inactivated H3N2 virus (H3N2i) in wild type strains of BALB/c and C57BL/6 mice, and CD4
and CD8 knockout (KO) mice. M2e5x VLP was better than H5 VLP in conferring cross protection
whereas H3N2i inactivated virus vaccine provided superior homologous protection. After M2e5x
VLP vaccination and challenge, BALB/c mice induced higher IgG responses, lower lung viral
loads, and less body weight loss when compared to those in C57BL/6 mice. M2e5x VLP but not
H3N2i immune mice after primary challenges developed strong immunity against a secondary
heterosubtypic virus as a model of future pandemics. M2e5x VLP and H5 VLP vaccines were able
to raise IgG isotypes in CD4 KO mice. T cells were found to contribute to cross protection by
playing a role in reducing lung viral loads. In conclusion, M2e5x VLP vaccination induced better
cross protection than HA VLP, and its efficacy varied depending on the genetic backgrounds of
mice, supporting the important roles of T cells.
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4.2

Results

4.2.1

C57BL/6 mice display lower levels of M2e-specific IgG responses after M2e5x VLP
vaccination than BALB/c mice.

We determined IgG isotype antibody responses to different influenza vaccine platform
antigens in BALB/c and C57BL/6 mice (Fig. 4.1). Groups of mice were i.m. immunized with 10
µg of M2e5x VLP, H5 VLP, or H3N2i. IgG isotypes specific for different influenza virus antigens
were determined at 2 weeks after boost immunization. The M2e5x VLP BALB/c mice showed
substantially high levels of IgG1, IgG2a, and IgG2b antibodies specific for M2e (Fig. 4.1A-D).
The H5 VLP BALB/c mice developed high levels of IgG2a and IgG2b antibodies specific for the
homologous rgH5N1 virus antigen. The level of IgG1 antibodies specific rgH5N1 virus were
significantly low in both BALB/c and C57BL/6 mice (Fig. 4.1E-H). The H3N2i group in BALB/c
mice raised significant levels of IgG1, IgG2a, and IgG2b antibodies specific for the same H3N2
vaccine virus (Fig. 4.1I-L). H5 VLP and H3N2i immune sera showed HA inhibition activity
against each antigen specific rgH5N1 and A/Philippines/2/82 (H3N2) virus respectively (Fig.
4.1M, N).
C57BL/6 mice immunized with M2e5x VLP also developed IgG2c and IgG2b isotype
antibodies binding to M2e antigens but at lower levels than BALB/c mice (Fig. 4.1A-D). Whereas,
comparably high levels of IgG2b antibodies specific for rgH5N1 and H3N2i virus antigens were
induced in the H5 VLP and H3N2i C57BL/6 groups (Fig. 4.1E-L).
Overall, both BALB/c and C57BL/6 mice developed differential levels of IgG isotypes
depending on the types of antigens and vaccine platforms. M2e5x VLP induced higher IgG1
isotype antibody responses than H5 VLP. Both BALB/c and C57BL/6 mice that were immunized
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with H3N2i vaccine developed IgG and class-switched IgG antibody responses at similarly high
levels. H5 VLP and M2e5x VLP vaccines showed a tendency of inducing IgG2c isotype
antibodies. Meanwhile, H3N2i immunization induced similar levels of class-switched IgG
antibodies in both BALB/c and C57BL/6 mice.
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Fig 1. IgG isotype antibody responses in BALB/c and C57BL/6 mice after vaccination with different influenza vaccines.

Figure 4.1 IgG isotype antibody responses in BALB/c and C57BL/6 mice after vaccination with different
influenza vaccines.
Each group of mice (n=10) was prime and boost i.m. immunized with 10 µg of M2e5x VLP (A-D), H5 VLP
(E-H), or inactivated A/Philippines virus (H3N2i) (I-L). Antibody levels of IgG (A, E, and I), IgG1 (B, F, and J),
IgG2a in BALB/c mice or IgG2c in C57BL/6 mice (C, G, and K), and IgG2b (D, H, and L) were detected by ELISA.
Sera were serially diluted and ELISA were performed by using vaccine specific antigens which are M2e peptide,
inactivated A/Indonesia (rgH5N1i), and H3N2i. Error bars indicates mean ± SEM. (M and N) HI titers. HI titers
against rgH5N1 (M) and H3N2 (N) were determined from immune sera of M2e5x VLP, H5 VLP, or H3N2i.
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4.2.2

M2e5x VLP is more effective in conferring cross protection than H5 VLP.

To determine cross protective efficacy, naïve and vaccinated mice were challenged with H3N2
(A/Philippines/82) virus (Fig. 4.2A). As expected, H3N2i vaccination induced complete protection
against the homologous H3N2 virus in both BALB/c and C57BL/6 mice (Fig. 4.2B, E). Also, H5
VLP immunization induced protection against homologous rgH5N1 virus (data not shown). In
contrast, H5 VLP vaccination did not induce protection against heterosubtypic H3N2 virus as
evidenced by severe body weight loss in BALB/c and C57BL/6 mice similar to naïve control (Fig.
4.2B, E). BALB/c mice immunized with M2e5x VLP showed protection against H3N2 virus
challenge despite a slight weight loss (Fig 4.2B). C57BL/6 mice immunized with M2e5x VLP
showed significant weight loss (15-18%) compared to the same vaccination of BALB/c mice (Fig
4.2E). Nonetheless, the M2e5x VLP immunized group of C57BL/6 mice showed less weight loss
indicating better cross protection than the naïve control or H5 VLP group (Fig 4.2E).
Protective efficacy was further confirmed by lung viral titers at day 7 after H3N2 virus
challenge (Fig. 4.2C, F). The naïve and H5 VLP groups showed the highest lung viral titers in a
range of 106 to 107 EID50 (per lung/ml) in contrast to the H3N2i group with lung viral clearance
below the detection limit. The M2e5x VLP group exhibited approximately 100 and 20 fold lower
lung viral titers compared to the H5 VLP group in BALB/c and C57BL/6 mice, respectively.
Overall, the results of lung viral titers show a correlation with protection as indicated by weight
loss.
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4.2.3

M2e5x VLP-immunized mice that survived primary infection develop immunity against
antigenically novel virus infection.
Outbreaks of pandemics are unpredictable and current vaccination is not effective in

preventing pandemics. To address this critical issue, the vaccinated mice that survived the H3N2
virus primary challenge were exposed 7 weeks later to the secondary infection with a lethal dose
of heterosubtypic H1N1 virus (A/California/07/2009). H3N2i vaccination did not provide
protection against the secondary H1N1 virus, as shown by severe weight loss (over 22% in
BALB/c mice) and no survivals (0%) in C57BL/6 mice (Fig. 4.2D, G). The M2e5x VLP group
exhibited the best protection and recovery against the secondary H1N1 virus infection in both
BALB/c and C57BL/6 mice (Fig. 4.2D, G). BALB/c mice with M2e5x VLP vaccination showed
better protection against secondary heterosubtypic virus challenge than the corresponding
C57BL/6 mouse group. In a similar trend, naïve BALB/c mice that survived primary H3N2
infection were protected against secondary H1N1 2009 virus (Fig. 4.2D) whereas naïve C57BL/6
mice surviving primary H3N2 infection were not well protected against secondary H1N1 2009
virus (Fig. 4.2G). Taken together, BALB/c mice with vaccination or primary H3N2 virus infection
showed stronger immunity during the secondary heterosubtypic H1N1 virus infection than
C57BL/6 mice suggesting mouse strain differences in protective efficacy by virus infection or
vaccination.
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Fig 2. Differential efficacy of protection by M2e5x VLP, H5 VLP, or H3N2i after primary H3N2 virus and secondary H1N1 virus

challenge
in BALB/c andefficacy
C57BL/6 mice.
Figure
4.2 Differential
of protection by M2e5x VLP, H5 VLP, or H3N2i after primary H3N2 virus and
secondary H1N1 virus challenge in BALB/c and C57BL/6 mice.
A. Time schedule for experiments of vaccination, 1st challenge infection with H3N2 virus, and 2nd challenge infection
with H1N1 virus. BALB/c (B and C) and C57BL/6 (E and F) mice were challenged with A/Philippines/2/82 (H3N2)
(H3N2v) at 4 weeks after boost with M2e5x VLP, H5 VLP, or H3N2i. Body weights were monitored for 14 days (B
and E). Lung viral titers were determined by the egg inoculation assay (C and F). The detection limit of EID50 was 1.7
Log10. At 7 weeks after 1st infection with A/Philippines/2/82/ (H3N2), BALB/c (D) and C57BL/6 (G) mice were
challenged with a different subtype of influenza virus (A/California/04/2009 H1N1) and body weight changes were
monitored for 14 days. H3N2 infection only group was the naïve infection group of B or E. Data represent the mean ±
SEM. Statistical significances were evaluated by 2-way ANOVA. **p<0.01, ****p<0.0001.
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4.2.4

BALB/c mice induce higher levels of M2e-specific T cell responses than C57BL/6
mice.

To better understand a difference in the cross protective efficacy between C57BL/6 and
BALB/c mice, we determined cellular immune responses by measuring the levels of IFN-γ and
IL-4 cytokines secreted into culture supernatants after in vitro stimulation with M2e peptides (Fig.
4.3). M2e5x VLP-immunized BALB/c mice showed significantly higher levels of IFN-γ and IL-4
cytokine secreting cells both in the lung and spleen cells collected day 7 post H3N2 challenge
compared to M2e5x VLP-immunized C57BL/6 mice (Fig. 4.3). These results indicate the
possibility that a genetic background of BALB/c mice is more effective in inducing M2e-specific
or virus specific T cell responses than that of C57BL/6 mice.
To further confirm the M2e-specific T cell responses, we carried out intracellular staining
and flow cytometry assays for quantification of CD4 and CD8 T cells secreting IFN-γ and
granzyme B in lungs and bronchoalveolar lavage fluids (BALF) at 7 days after viral challenge.
Significantly higher levels of IFN-γ in CD4 T cells were detected in M2e5x VLP-immunized
BALB/c than C57BL/6 mice (Fig. 4.4). In contrast, C57BL/6 mice showed much lower levels of
IFN-γ secreting CD4 T cells in lungs and BALF than BALB/c mice (Fig. 4.4). IFN-γ secreting
lung CD4 T cells induced by M2e5x VLP vaccination and virus challenge were at a higher level
compared to that in naïve mice after challenge (Fig. 4.4D). In BALF, M2e5x VLP immunized
C57BL/6 mice showed a lower number of IFN-γ secreting CD4 T cells than the naïve mouse
control (Fig. 4.4B). Although the reason for this odd finding is not clear in C57BL/6 mice, this
might be due to the delayed recruitment of the effector CD4 T cells to the airway area as a result
of better control of lung viral loads. In lungs, C57BL/6 mice immunized with M2e5x VLP showed
significantly higher IFN-γ secreting CD4 T cells than the naïve mouse control (Fig. 4.4D) in a
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similar pattern with the case in BALB/c mice. The combined IFN-γ secreting CD4 T cells in BALF
and lungs were significantly higher in M2e5x VLP-immunized C57BL/6 mice (Fig 4.4C, D).
M2e5x VLP vaccination did not increase IFN-γ secretion from antigen-specific CD8 T cells
(Supplementary Fig. 4). However, BALB/c mice induced significantly higher levels of granzyme
B secreting CD8 T cells than C57BL/6 mice at day 7 after viral infection (Fig. 4.5). In summary,
BALB/c mice have a genetic background resulting in higher T cell responses to M2e5x VLP
vaccination and influenza viral infection.
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Fig 3. Cytokine producing T cell responses in C57BL/6 and BALB/c mice.

Figure 4.3 Cytokine producing T cell responses by M2e5x VLP immunization in C57BL/6 and BALB/c mice.
A. IFN-γ-secreting cells in lungs. B. IL-4-secreting cells in lungs. C. IFN- γ-secreting cells in splenocytes. D. IL-4secreting cells in splenocytes. Lung cells and splenocytes were isolated from C57BL/6 and BALB/c mice previously
immunized with M2e5x VLP at day 7 post-challenge (A/Philippines/2/82 H3N2). Cytokine-producing cell spots were
counted by ELISPOT reader. Data represent the mean ± SEM. Statistical significances were evaluated by 2-way
ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

34

A

BALF

LUNG

M2e5x VLP

Naive

M2e5x VLP

Naive

BALB/c

GrzB

GrzB

C57BL/6

IFNg

IFNg
C

B

# Cells

8000

CD4+ / IFNγ+
****
****

CD4+ / IFNγ+

80000

****

Naive

M2e5x VLP

****

Naive

60000

6000

*

4000

***

2000
0

Lung
M2e5x VLP

# Cells

BALF
10000

BALB/c

C57BL/6

40000

***

20000
0

BALB/c

C57BL/6

Fig 4. Intracellular cytokine staining of CD4+ T cells in C57BL/6 and BALB/c mice.

Figure 4.4 Intracellular cytokine staining of CD4+ T cells under the condition of M2e5x VLP immunization in
C57BL/6 and BALB/c mice.
A. Representative flow cytometry profiles of IFN-γ- and Granzyme B-secreting CD4+ T cells in BALF and lungs. B.
The cellularity of IFN- γ-secreting CD4+ T cells in BALF. C. The cellularity of IFN- γ-secreting CD4+ T cells in lungs.
The numbers of cells were indicated as the number per mouse (C and D). After gating CD4+ cells, IFN-γ+ or Granzyme
B+ cells were measured by flow cytometry of intracellularly stained cells. Data represent the mean ± SEM. Statistical
significances were evaluated by 2-way ANOVA. *p<0.05, ***p<0.001, ****p<0.0001.
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Supplementary Fig 1. Intracellular cytokine staining of CD8+ T cells in C57BL/6 and BALB/c mice.

Figure 4.5 Intracellular cytokine staining of CD8+ T cells in C57BL/6 and BALB/c mice.
Flow cytometry profiles of IFN-γ- and Granzyme B-secreting CD8+ T cells in BALF and lungs. After gating CD8+
cells, IFN-γ+ or Granzyme B+ cells were measured by flow cytometry of intracellularly stained cells.
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4.2.5

M2e5x VLP and H5 VLP vaccines induce IgG isotype-switched antibodies in CD4
knockout mice at different levels.
CD4 T cells are known to play critical roles in inducing isotype-switched IgG antibodies.67

To determine the roles of T cells in inducing IgG isotype-switched antibodies and protective
immunity after influenza vaccination, we immunized CD4 knockout (CD4 KO) and CD8 knockout
(CD8 KO) mice (Fig. 4.7). Vaccine dose and immunization regimens were the same as described
in wild type mice above. CD4 KO mice immunized with M2e5x VLP induced significant levels
of M2e-specific IgG antibodies (Fig. 4.6A-D). CD8 KO mice immunized with M2e5x VLP
developed similar levels of M2e-specific IgG antibodies (Fig. 4.6A-D). H5 VLP immunization
was able to induce rgH5N1 virus-specific IgG antibodies in a similar trend with M2e5x VLP in
both T cell KO mice (Fig. 4.6E-H). CD4 KO mice immunized with H3N2i induced significantly
lower levels of H3N2 virus-specific IgG, IgG2c, and IgG2b isotype antibodies (Fig. 4.6I-L) than
those in wild type C57BL/6 mice (Fig. 4.1I-L). However, H3N2i immunized CD8 KO mice
developed similar levels of H3N2 virus-specific IgG antibodies with wild type mice (Fig. 4.6I-L).

4.2.6

T cells contribute to cross protection by M2e5x VLP vaccine.

The roles of CD4 and CD8 T cells in conferring vaccine-induced protection were determined
using knockout mouse models (CD4 KO, CD8 KO) after vaccination and challenge (Fig. 4.7).
M2e5x VLP vaccinated CD4 KO mice displayed a progressive weight loss to a similar degree as
in naïve CD4 KO mice but showed a better recovery at later time points (Fig. 4.7B). A high lung
viral titer at day 7 after challenge was observed in the M2e5x VLP CD4KO group, which is similar
to the one observed in naïve infection (Fig. 4.7C), suggesting a role of CD4 T cells in M2e-immune
mediated cross protection. H3N2i vaccination of CD4 KO induced protection against homologous
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virus challenge although there was a substantial lung viral titer in CD4 KO mice (Fig. 4.7C).
H3N2i immune sera from CD4 KO mice significantly inhibited the HA activity of homologous
virus (Fig. 4.6 M, N). These results suggest that CD4 T cells play a role in preventing severe weight
loss and clearing lung viral loads by M2e5x VLP vaccination. As expected from high levels of
IgG antibodies, H3N2i vaccinated CD8 KO mice showed no weight loss after homologous H3N2
virus challenge (Fig. 4.7E) similar to the one induced in C57BL/6 mice (Fig. 4.2E). M2e5x VLP
vaccinated CD8 KO mice showed similar infection symptoms and high lung viral loads similar to
naïve CD8 KO mice against H3N2 virus challenge (Fig. 4.7E, F). Thus, CD8 T cells also play an
important role in preventing severe weight loss and in clearing lung viral loads in M2e5x VLP
immunized mice.
CD4 KO mice with M2e5x VLP vaccination showed a moderate level of protection against
secondary heterosubtypic virus challenge (Fig. 4.7D) in a similar pattern with the corresponding
C57BL/6 mouse groups (Fig. 4.2G). CD8 KO mice immunized with M2e5x VLP showed more
severe body weight loss compared to CD4 KO and wild type mice (Fig. 4.7G). Taken together,
M2e5x VLP-mediated immunity is partially dependent on CD8 T cells during the secondary
heterosubtypic virus infection whereas primary infection-mediated immunity is related with both
CD4 and CD8 T cells.
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Fig 5. IgG isotype antibody responses in CD4 KO and CD8 KO mice after vaccination with different influenza vaccines.

Figure 4.6 IgG isotype antibody responses in CD4 KO and CD8 KO mice after vaccination with different influenza
vaccines.
Each group of CD4 KO and CD8 KO mice (n=10) was prime and boost i.m. immunized with 10 µg of M2e5x VLP (AD), H5 VLP (E-H), or H3N2i (I-L). Antibody levels of IgG (A, E, and I), IgG1 (B, F, and J), IgG2c (C, G, and K), and
IgG2b (D, H, and L) were detected by ELISA. The same influenza antigens were used for ELISA as described in Fig. 2.
Error bars indicates mean ± SEM. (M and N) HI titers. HI titers against rgH5N1 (M) and H3N2 (N) were determined
from immune sera of M2e5x VLP, H5 VLP, or H3N2i.
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Fig 6. Efficacy of protection in CD4 KO and CD8 KO mice by different influenza vaccines after primary H3N2 virus and
secondary H1N1 virus challenge.

Figure 4.7 Efficacy of protection in CD4 KO and CD8 KO mice by different influenza vaccines after primary
H3N2 virus and secondary H1N1 virus challenge.
A. Time schedule for experiments of vaccination, 1st challenge infection with H3N2 virus, and 2nd challenge infection
with H1N1 virus. CD4 KO (B, C, and D) and CD8 KO (E, F, and G) mice were challenged with A/Philippines/2/82
(H3N2) (H3N2v) at 4 weeks after boost with M2e5x VLP or H3N2i. Body weights were monitored for 14 days. Lung
viral titers were determined by the egg inoculation assay (C and F). The detection limit of EID50 was 1.7 Log10. At 7
weeks after 1st infection with A/Philippines/2/82/ (H3N2), CD4 KO (D) and CD8 KO (G) mice were challenged with
a different subtype of influenza virus (A/California/04/2009 H1N1) and body weight changes were monitored for 14
days. H3N2 virus infection only group was the naïve infection group of B or E. Data represent the mean ± SEM.
Statistical significances were evaluated by 2-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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4.2.7

M2-specific immune sera play a role in conferring cross protection.
M2e5x VLP was found to induce significant levels of M2e-specific antibodies in C57BL/6,

CD4 KO, and CD8 KO mice. Thus, we determined the roles of M2e immune sera in conferring
protection independent of T cell immunity as detailed in the methods section. Naïve mice were
infected with a mixture of H3N2 virus and immune sera collected from different genotypic M2e5x
VLP immune or naïve mice, and then weight changes and survival rates were daily monitored (Fig.
4.8A). M2e5x VLP immune sera from CD4 KO and CD8 KO mice were found to contribute to
protection against H3N2 virus at a similar level as observed in M2e5x VLP immune sera from
C57BL/6 mice. Consistent with these body weight monitoring results, M2e5x VLP-immune sera
from CD4 KO mice representatively showed significantly lower levels of lung viral titers than
naïve control sera (Fig. 4.8B). Taken together, these results suggest that M2e-immune sera from
different strains and genotypes of mice confer similar levels of protection regardless of genetic
backgrounds and T cell immunity, preventing severe weight loss, and increasing survival rates and
recovery.
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Figure 4.8 M2e antibodies in T cell deficient mice show similar capacity to confer protection in naïve mice.
Immune sera collected from immunized C57BL/6, CD4 KO, and CD8 KO mice were incubated with influenza virus
(A/Philippines/2/82 H3N2). Naive mice were intranasally infected with a mixture of a lethal dose of influenza virus
and immune sera or naïve sera. Body weights were monitored for 14 days (A). Lung viral titers day 7 post infection
were determined by the egg inoculation assay (B). The detection limit of EID50 was 1.7 Log10.
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4.3

Discussion
Most subunit vaccines including cross protective influenza A virus M2 vaccines have been

investigated in BALB/c mice.34,35,39,40,68-70 A limited set of influenza M2 vaccine studies has been
performed in C57BL/6 mice.44,71 In our previous studies34,68, we have developed an M2e targeting
M2e5x VLP vaccine and studied cross protective efficacy mostly in BALB/c mice. In this study
of comparing HA-based H5 VLP and inactivated whole influenza virus (H3N2i) vaccines, we
investigated heterosubtypic cross protective efficacies of M2e5x VLP in mice with different
genetic backgrounds and the roles of T cells in inducing IgG antibodies and protection using
knockout mutant mouse models. M2e5x VLP vaccination induced higher levels of IgG antibodies
and protective efficacy in BALB/c mice than that in C57BL/6 mice. The efficacy of cross
protection by M2e5x VLP was higher than that by H5 VLP but lower compared to homologous
protection by H3N2i immunization. M2e5x VLP vaccinated mice that were protected against
primary challenge with H3N2 virus have developed future immunity to secondary infection against
H1N1 virus, which was not induced in H3N2i immunized mice. M2e5x VLP and H5 VLP vaccines
were able to raise substantial amounts of isotype-switched IgG antibodies in CD4 KO mice
although antibody levels were lower than those in CD8 KO and C57BL/6 mice. In addition to
immune sera containing M2e specific antibodies, both CD4 and CD8 T cells were found to play
roles in clearing lung viral loads and in better recovery after M2e5x VLP vaccination and virus
challenge.
Efficacy studies in inbred mouse strains might not be predictive in genetically diverse human
populations. A previous study reported that no IgG antibodies specific for M2e were induced in
C57BL/6 mice that were primed with M2 DNA and boosted with M2 recombinant adenovirus.71
Also, antibody responses and protection to HA DNA vaccination were reported to be lower in
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C57BL/6 mice than those in BALB/c mice.72 In this study, M2e5x VLP raised similar or lower
levels of IgG, IgG2c, and IgG2b isotype antibodies in C57BL/6 mice compared to those in BALB/c
mice. Whereas, H5 VLP and H3N2i vaccines developed similar levels of IgG isotype antibodies
in C57BL/6 and BALB/c mice. M2e5x VLP and H5 VLP vaccines were immunogenic and able to
induce IgG isotype antibodies even in CD4 KO mice, suggesting an alternative pathway of
inducing CD4-independent IgG antibodies. H3N2i vaccine appears to require CD4 T helper cells
for effective induction of IgG antibodies. Presenting HA proteins on the VLP platform was shown
to induce Th1 type antibody responses and enhanced protection compared to soluble form HA
protein56 or split influenza vaccines73. In line with these results, H1 VLP was more effective in
developing IgG antibodies in CD4 KO mice compared to the same H1N1 strain inactivated split
influenza virus vaccine (data not shown). VLP itself appears to grant immunogenic properties to
the antigens on it. VLP vaccines were reported to stimulate dendritic cells in vitro and in vivo, and
to produce inflammatory cytokines.74 In addition, VLP-loaded dendritic cells stimulated the
induction of T cell responses in vitro.75 These unique properties of VLP vaccines likely attribute
to inducing Th1 type IgG antibodies in BLAB/c and C57BL/6 mice as well as in CD4 KO and
CD8 KO mice.
Despite the result that M2e5x VLP had immunogenic properties of inducing IgG antibodies,
the protective efficacy varied in genetically different strains and mutant mice. M2e5x VLP showed
higher cross protection in BALB/c mice than that in C57BL/6 mice. The efficacy of M2e5xVLP
in lowering lung viral replication in CD4 KO and CD8 KO mice was even lower compared to that
in C57BL/6 mice. Although H3N2i vaccination induced protection preventing weight loss against
homologous primary virus even in CD4 KO mice, H3N2i immune mice were not protective during
heterosubtypic secondary virus infection at a later time despite significant viral replication during

43

the first infection. In contrast, infection permissive M2e5x VLP vaccination after primary
challenge developed sufficient immunity in BALB/c mice against secondary heterosubtypic virus,
consistent with previous studies in BALB/c mice.53,66,76 C57BL/6 mice with M2e5x VLP showed
lower efficacy of secondary immunity than BALB/c mice, but significantly higher efficacy than
naïve C57BL/6 mice with high viral loads during primary infection. High viral replication during
primary infection accompanying severe weight loss in naïve C57BL/6 mice was not effective in
inducing immunity against secondary heterosubtypic virus infection. This aspect provides
evidence of beneficial effects on developing future immunity by inducing cross protective M2e
immunity as shown in M2e5x VLP-immunized C57BL/6 mice. The efficacy of future immunity
against secondary virus infection was diminished in CD8 KO mice, suggesting that both CD8 T
cells and M2e antibodies might be major immune correlates contributing to protection against
heterosubtypic virus infection. In addition, this study provides evidence that high viral replication
in naïve C57BL/6 mice would not be sufficient for developing immunity against heterosubtypic
virus probably due to less efficacy of inducing Granzyme B secreting CD8 T cell responses in
C57BL/6 mice compared to those in BALB/c mice.
Several mechanisms have been reported for protection by M2e-immunity. Immune sera
containing M2e antibodies regardless of strains of mice conferred similar levels of protection in
naïve mice. Thus, M2e antibodies induced in C57BL/6 and CD4 KO mice may have similar
capability of protection. Since lung viral loads were higher in CD4 KO and CD8 KO mice than
those in C57BL/6 mice in the M2e5x VLP group, it is possible that both CD4 and CD8 T cells
play a role of effector functions in lowering viral loads.77 Alternatively, CD4 T cells may help to
sustain the cytotoxic T cell response. Other mechanisms for M2e immune mediate protection
include Fc receptor (FcR)57,68,78, FcR-mediated opsonophagocytosis by macrophages39, and
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natural killer cells 35. It appears that FcR is a key mediator for conferring cross protection by M2e
antibodies. In addition, this study highlights the impacts of host genetic backgrounds and T cell
responses in cross protection.
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4.4

Conclusion
This study demonstrated that different levels of immune responses are developed

depending on the genetic background of the host. M2e5x VLP induced strong cross protective
immunity compared to other types of vaccines including H5 VLP and inactivated whole virus and
showed unique patterns of immune responses in different wild type mouse strains. BALB/c mice
developed higher humoral and cellular responses than C57BL/6 mice by M2e5x VLP, supporting
its strong vaccine efficacy in the BALB/c strain. This strain dependent protective efficacy was
mediated by different levels of T cell responses by both CD4 and CD8+ T cells. Thus, the results
suggest that M2e5x VLP immunization confers better cross protection than HA based vaccines
such as H5 VLP and inactivated whole virus, and its efficacy is determined by T cell responses
which vary depending on the genetic backgrounds of hosts.
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5

CHAPTER 3. COMPLEMENT C3 PLAYS A KEY ROLE IN INDUCING

HUMORAL AND CELLULAR IMMUNE RESPONSES AND PROTECTION BY
INFLUENZA VIRUS M2 EXTRACELLULAR DOMAIN-BASED VACCINE.

5.1

Summary
The complement pathway is involved in eliminating antigen immune complexes. However, the

role of C3 complement system remains largely unknown in influenza virus M2 extracellular (M2e)
or hemagglutinin (HA) immune-mediated protection. We found that complement protein C3 was
required for effective induction of immune responses to influenza virus M2e or HA vaccination
and influenza virus infection, which include M2e-specific isotype-switched antibodies and effector
CD4 and CD8 T cells. C3 knockout (C3 KO) mice after active immunization with M2e-based
vaccine were not protected although low levels of M2e specific antibodies protective after passive
administration with virus. Whereas, C3 KO mice that were immunized with HA-based vaccine
were protected against virus challenge. In naïve condition, C3 KO mice showed impaired cellular
phenotypes of innate immune cells such as macrophages, monocytes, and dendritic cells. The
findings in this study suggest that C3 is required for effective induction of adaptive immune
responses after influenza vaccination.
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5.2

5.2.1

Results

Induction of IgG antibodies to viral infection is impaired in C3 deficient mice.
To determine the antibody phenotypes as a result of C3 deficiency in naïve mice, we

compared natural antibody levels between wild type (WT, C57BL/6) and C3 knock-out (KO) mice
(Fig. 5.1A). There were no differences in IgM and IgG isotypes (IgG1, IgG2c, IgG2b) in sera from
WT and C3 KO mice in the absence of antigen exposure, indicating no defect in maintaining
antigen non-specific natural antibodies in C3 KO mice. However, after virus infection with
A/Philippines/2/1982 H3N2 (A/Phil H3N2), C3 KO mice rarely induced IgG antibodies at day 7
post-infection (Fig. 5.1D-G). At a later time-point after viral infection, C3 KO mice could induce
moderate levels of H3N2 virus specific IgG antibodies, which were significantly lower than those
in WT mice (Fig. 5.1H-K). In line with a defect in inducing virus specific antibodies, C3 KO mice
were found to be more susceptible to influenza virus infection compared to WT mice (Fig. 5.1B
and C). The sub-lethal dose (1.5 LD50) of A/Phil H3N2 virus for WT mice lead to the 100%
lethality in C3 KO mice and a 10-fold lower dose (0.15 LD50) induced a comparable level of weight
loss in C3 KO mice (Fig. 5.1B and C). These results suggest that C3 plays a critical role in inducing
IgG antibodies and conferring protection in response to viral infection.
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5.2.2

C3 deficient mice are less effective in inducing M2e-specific IgG responses after
M2e5x VLP immunization.

To evaluate the role of C3 in mediating non-neutralizing M2e immunity, we compared IgG
antibody levels induced in WT and C3 KO mice after M2e5x VLP vaccination (Fig. 5.2). Groups
of mice in WT and C3 KO mice were intramuscularly immunized with 10 µg of M2e5x VLP by a
prime boost strategy. At 2 weeks after prime (Fig. 5.2A-D) and boost (Fig. 5.2E-H) immunization,
IgG isotype antibodies specific for M2e were measured by ELISA.
Overall, M2e5x VLP-immunized WT mice showed high levels of M2e-specific IgG1 and
IgG2c, and IgG2b antibodies both after prime (Fig. 5.2A-D) and boost (Fig. 5.2F-H)
immunization. However, the levels of M2e-specific IgG isotypes were significantly lower in C3
KO mice than those in WT mice after prime and boost (Fig. 5.2A-H). These results indicate that
C3 protein is important for the production of antigen-specific IgG antibodies after M2e5x VLP
vaccination.
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5.2.3

M2e5x VLP immune C3 deficient mice are not protected after challenge.
To determine whether the complement system has a role in M2e-mediated cross-protection,

the groups of WT and C3 KO mice were prime and boost immunized with M2e5x VLP at an
interval of 3 weeks and followed by challenge infection with sub-lethal dose of A/Phil H3N2 virus
3 weeks later (Fig. 5.3). C3 KO mice showed approximately 10-fold higher susceptibility to
influenza virus infection, indicating a role of C3 in innate immunity (Fig. 5.1). Thus, we used a
10-fold lower dose to infect C3 KO groups than that of WT groups in order to evaluate the
protective efficacy of the vaccine. As expected, WT mice immunized with M2e5x VLP showed a
moderate weight loss (10-12%) (Fig. 5.3A and B). Whereas, influenza virus infection resulted in
significant weight loss in C3 KO mice immunized with M2e5x VLP, displaying no difference
between the immunized and naïve C3 mouse groups (Fig. 5.3C and D). Protective efficacy was
further confirmed by lung viral titers at day7 post infection. M2e5x VLP vaccination of WT mice
conferred 100-fold lower lung viral titers than the naïve control, but this protection of viral
clearance was not observed in vaccinated C3 KO mice (Fig. 5.3E). These results suggest that C3
is an essential immune component in M2e-mediated protection.
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Figure 5.3 Vaccination with M2e5x VLP does not protect C3 KO mice against heterosubtypic virus infection.
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5.2.4

C3 KO mice display a defect in generating antibody-secreting and germinal center
phenotypic cells.
Developing long-lived antibody-secreting cell responses is important for providing long-

term protection. We determined whether C3 would play a role in generating long-lived plasma
cells and germinal center phenotypic B cells. In vitro antibody production was measured from
cultured cells of bone marrow and spleens collected from immune mice at 7 days after influenza
virus challenge (Fig. 5.4). As previously reported, both bone marrow cells and splenocytes from
the WT group immunized with M2e5x VLP secreted high levels of M2e-specific IgG antibodies,
indicating effective development of M2e-specific antibody secreting cells (Fig. 5.4A and B).
However, C3 KO mice showed significantly lower production of M2e-specific IgG antibodies
compared to WT mice in both bone marrow cells and splenocytes (Fig. 5.4A and B). In addition,
C3 deficiency resulted in lower levels of germinal center phenotypic (GL7+) B cells in spleens
(Fig. 5.4C and D). These results suggest that C3 plays a key role in the development of antigen
specific antibody-secreting cells and germinal center phenotypic B cells.
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5.2.5

C3 is required to develop effective M2e-specific cellular immune responses.

It has been known that T cell responses contribute to broadening cross protective immunity in
M2-mediated immune responses.43,79 Thus, we determined whether C3 would be required for
developing M2e-specific T cell immunity. Lung cells and splenocytes were collected at 7 days
after challenge and cultured in vitro. After stimulation with an M2e peptide, cytokine producing
cell spots were counted as an indicator of T cell responses (Fig. 5.5). M2e5x VLP immunized
group showed over 7-fold higher levels of IFN-g and 5-fold higher levels of IL-4 secreting lung
cells compared to naïve control group in WT mice as previous reported (Fig. 5.5A and B).
However, C3 KO mice failed to develop cytokine producing T cells, showing no difference
between M2e5x VLP immunized and naïve groups (Fig. 5.5A and B). A similar pattern was
observed in splenocyte cultures showing high levels of IFN-g and IL-4 secreting lung cells and
splenocytes only in WT mice immunized with M2e5x VLP, but not in C3 KO mice (Fig. 5.5C and
D).
To investigate further details of M2e-specific T cell phenotypes using intracellular cytokine
staining and flow cytometry assays (Fig. 5.6), lung cells and splenocytes were harvested from WT
and C3 KO mice previously immunized with M2e5x VLP at 7 days after virus infection. M2e5x
VLP immunized WT mice showed significantly high numbers of IFN-g secreting CD4 and CD8+
T cells in lungs (Fig. 5.6A and B) and spleens (Fig. 5.6C and D). These results suggest that C3 is
required to develop effective M2e-specific T cell responses.
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5.2.6

M2e-specific antibodies induced in C3 KO mice are protective.
Since M2e5x VLP immunized C3 KO mice were not protected (Fig 5.3), we determined

whether M2e-specific antibodies induced in C3 KO mice would have protective capability. Naïve
WT mice (BALB/c) were infected with a mixture of heat inactivated M2e5x VLP immune sera
and a lethal dose of H3N2 influenza virus and body weights were monitored for 14 days (Fig. 5.7).
Naive mice that received WT mouse and C3 KO mouse M2e immune sera together with H3N2
virus showed 19 % and 24 % weight loss respectively and then recovered normal weight. A lower
level of M2e specific antibodies in C3 KO mouse immune sera appears to contribute to more
weight loss. Naïve mice that received naïve sera and virus did not survive, suggesting that M2especific antibodies induced in C3 KO mice have protective capacity.
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5.2.7

HA VLP vaccinated C3 KO mice induce HA inhibiting antibodies and protection.
Since C3 KO mice with M2e5x VLP could not confer protection, we determined whether

HA (A/Indonesia/05/2005) VLP vaccines would induce protection in C3 KO mice. Groups of WT
and C3 KO mice were intramuscularly immunized with 10 µg of H5 HA VLP. H5 HA VLPimmunized WT mice showed higher levels of virus-specific IgG1 and IgG2c, and IgG2b
antibodies both after prime (Fig. 5.8A-D) and boost (Fig. 5.8E-H) immunization. Although C3
KO mice induced lower amounts of virus-specific IgG isotypes than those in WT mice after H5
HA VLP vaccination, IgG antibody levels were substantially high in C3 KO mice (Fig. 5.8A-H).
Consistent with the levels of binding IgG antibodies, immune sera from C3 KO mice showed
significant levels of HI titers in a range of 128 to 256 although these levels of HI titers in C3 KO
mice were lower than those in WT immune sera (Fig. 5.8K). C3 KO mice immunized with H5
VLP were protected against 1.5 LD50 homologous rgH5N1 influenza virus (A/Indonesia/05/2005)
without displaying weight loss (Fig. 5.8I and J). These results suggest that neutralizing antibodymediated protection is independent of C3 roles.
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5.3

Discussion
The complement system has been considered to play an essential role in the control of influenza

virus infections, including recognition and elimination of virus particles.41,42,80 It is able to mediate
directly viral clearance including neutralization, opsonisation, lysis, and phagocytosis via
complement receptors.81 Moreover, the complement system has been known to modulate the
adaptive immune responses via multiple mechanisms.49 In the present study, we described that the
complement system has a critical role in conferring M2e-mediated cross protection through the
development of M2e-specific humoral and cellular immune responses.
First, our results explained that complement C3 is essential for inducing M2e-specific IgG
isotypes and B cell immunity. Immunization with M2e5x VLP in C3 KO mice failed to fully elicit
M2e-specific IgG isotype antibodies (Fig. 5.2) and IgG memory response (Fig. 5.4) compared to
wild type control mice. In addition, virus-specific IgG levels were significantly low in C3 KO mice
(Fig. 5.1A) even though natural antibody levels were normal in C3 KO mice (Fig. 5.1D). These
results suggest that complement C3 has an important role in the formation of humoral memory
responses and antibody isotype switching in M2e-mediated immunity.
The role of the complement system in influenza M2e-mediated immunity remains
controversial. Previously, passive transfer approaches of M2e-specific antibodies have
demonstrated controversial results which explain the role of complement C3. Jegerlehner et al.
showed that C3 KO mice passively immunized with M2-HBc immune serum were survived at a
similar level with those of WT mice, indicating that complement C3 is not required for M2e
antibody-mediated cross protection.35 In contrast, Wang et al. explained that complement C3 is
essential in lung viral clearance of infected mice by passive transfer of anti-M2e monoclonal
antibodies.38 However, it has not been well understood how complement C3 functions in the active
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immunization condition of the M2e vaccine. Based on our data, M2e5x VLP immunized C3 KO
mice induced moderate levels of IgG isotype antibodies even though those were significantly lower
than WT mice. In vivo protection test showed no defect in the cross protective ability of M2especific antibody itself generated from C3 KO mice (Fig. 5.7). Although M2e-immune sera from
C3 KO mice contain lower amount of M2e-specific antibodies than those from WT mice (Fig.
5.2), immune sera-mediated protection was not affected. A possible explanation is that the amount
of M2e-specific antibodies induced in C3 KO mice is enough to confer the protection mediated by
direct interaction between antibodies and influenza virus particles. This is supported by our
additional data that C3 deficiency does not affect the neutralizing antibody-mediated homologous
protection even though the antibody level was lower than in WT condition (Fig. 5.8). Based on
these results, we concluded that the more amount of antibodies does not always confer additional
effects in the antibody-mediated protection.
The failure to produce the normal amount of M2e-specific antibodies in the C3 deficient
condition is able to be explained by reduced number of GC B cells (Fig. 5.4C and D). Two possible
mechanisms might be able to explain these failures in M2e-specific IgG induction and GC B cell
response in the C3 deficient condition; (1) impaired helper CD4+ T cell priming or (2) abnormal
functions of antigen presenting cells. Previous report has demonstrated that C3 deficiency might
cause inefficient delivery of viral antigens to professional APCs, leading to impaired priming of
influenza virus specific CD4+ helper T cells.52 Moreover, it was reported that impaired T cell
priming by C3 deficiency is linked to the defect in DC migration from the lung to the draining
lymph nodes.82
In addition to T cell priming, our results demonstrated that complement C3 is necessary for
both recruitment and effector function of T cells. The frequency and number of M2e-specific IFN-
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g-producing CD4+ and CD8 T+ cells were reduced at the site of infection in C3 KO mice (Fig. 5.6A
and B) as well as spleen (Fig. 5.6C and D). Based on these data, we concluded that complement
C3 regulates recruitment into the lungs and antiviral effector functions of M2e-specific both CD4+
and CD8+ T cells. This may expand the precious finding that T cell depletion causes reduced cross
protection by M2e targeting vaccine.43,79
We additionally investigated how innate immune cells are affected in the complement C3
deficient condition. Our data demonstrated that C3 deficiency leads to significant reductions in
innate immune cells in the basal level, including macrophages and major subsets of dendritic cells.
This impaired innate immune system by C3 deficiency may cause inefficient delivery of vaccine
antigens to antigen presenting cells (APCs) and attenuate T cell priming.
Reduced antigen-specific IgG production in the C3 deficient condition was also observed in a
different type of antigens such as live influenza virus and H5 HA VLP vaccine. Homologous
protection by the HA targeting vaccine was not affected by the absence of complement C3.
Immunized C3 KO mice with H5 HA VLP vaccine did not show weight loss after homologous
influenza virus infection. HA-specific neutralizing antibodies induce sterilizing immunity against
strain-matched influenza viruses, leading to complete protection.7 Reduced HI activity of
antibodies from C3 KO mice correlates with lower amounts of antibodies compared to WT mice
but these HI titers of 128 to 256 would be sufficient for homologous protection independent of C3
(Fig. 5.8K). We previously reported the similar finding in the Fc receptor deficient condition,
demonstrating that Fc receptor KO mice immunized with an inactivated virus vaccine (A/PR/8/34
H1N1) showed the HI titer around 128 and good sterilizing homologous protection.57
It has been reported that C3 KO mice themselves are highly susceptible to viral infection.52,83
We confirmed that C3 deficiency results in severe weight loss and rarely induced virus-specific
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IgG antibodies after infection with the same dose of influenza virus between WT and C3 KO mice
(Fig. 5.1). Natural antibody levels did not show any significant difference in C3 KO mice (Fig.
5.1D). However, C3 KO mice showed significant defects in basal levels of innate immune cells
such as macrophages, monocytes, and dendritic cells in their peritoneal exudates (Supplementary
Fig. 5.9). Thus, we concluded that high susceptibility of C3 KO mice to viral infection may be due
to their defects in innate immune system.
In summary, our results demonstrate that complement protein C3 is required for effective
development of adaptive immune responses to influenza virus M2e and HA VLP vaccination as
well as virus infection. We found several defects which were caused by C3 deficiency, including:
i) reduced M2e-specific IgG isotype antibodies, ii) impaired induction of effector CD4+ and CD8+
T cells, and iii) abnormal innate immune cell phenotypes. Taken together, the data support a
hypothesis that complement C3 is important for both M2e-specific humoral and cellular immune
responses to be fully induced, conferring effective cross protection against influenza virus
infection.
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5.4

Conclusion
This study indicated that complement protein C3 is essential in inducing immune responses

to influenza virus infection and vaccination, which include M2e-specific isotype-switched
antibody production and inducing M2e-specific effector CD4 and CD8 T cells. C3 knock-out (C3
KO) mice showed lower levels of M2e-specific IgG isotype antibodies after M2e vaccination, and
no control of lung viral replication and no recovery from weight loss upon challenge infection
compared to those in wild type (WT) mice. Whereas, C3 KO mice were protected against
homologous virus after immunization with neutralizing antibody inducing hemagglutinin-based
vaccine despite lower levels of antibodies than those in WT mice. Those results revealed the
critical roles of C3 complement in inducing humoral and cellular immune responses to influenza
virus infection and immunization with M2e or HA vaccines. C3 was found to be required for
protection by M2e-based but not by HA-based active vaccination as well as for maintaining innate
antigen presenting cells. Findings in this study have insight into better understanding the roles of
C3 complement in inducing effective adaptive immunity and in non-neutralizing M2e immune
mediated protection.
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6
6.1

CONCLUSIONS

Cross protective influenza vaccines
Current influenza vaccines are effective in conferring protection against strain-matched

influenza viruses when the HA antigenic strains is closely matched with vaccines.13 This is due to
the fact that genetic mutations of the hemagglutinin (HA) are frequently occurred, leading to viral
escape from existing immunity.5,84 Since the immune responses induced by current vaccines are
narrow and limited in specific strains, an annual update is required which strains will be most
likely circulating and targeted.12,84 This annual process to produce seasonal influenza vaccines is
time-consuming and costly.5,13 In addition to the economic burden, current vaccines are not
appropriate to confer protection against newly emerging pandemic influenza strains which have
distinct HA antigenicity and appear at irregular intervals.5,13 Therefore, several approaches have
been tested to develop cross protective influenza vaccines which induce effective immunity to
different subtypes of influenza virus strains.5 For that, several viral antigens, which are highly
conserved through most strains of influenza A viruses, have been considered as targets for cross
protective influenza vaccines.12,85 Among influenza viral proteins, multiple conserved targets have
been evaluated as possible candidates for cross protective influenza vaccines, including HA stalk
domain, the extracellular domain of M2 (M2e), nucleoprotein (NP), matrix protein 1 (M1) and two
highly conserved sequences near the NA enzymatic site (Table 1).12 In this study, three different
influenza antigens, which include HA, NA, and M2e, were investigated as candidates for possible
cross protective vaccine development (Figure 6.1).
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Table 6.1 Viral targets of universal influenza vaccines.

6.2

Protection mechanisms of the antibody-mediated immunity
The strategy of current influenza vaccination is to induce neutralizing antibodies targeting

highly changeable HA, which does not provide effective protection against antigenically mutated
viruses and pandemics.12,85 In the effort to overcome this limitation of current vaccines, new
vaccine strategies have been investigated, targeting relatively more conserved viral antigens.
Among possible viral antigens, the extracellular domain (M2e) of influenza virus M2 protein has
been extensively studied as a vaccine target and utilized in various carrier vehicles and vaccine
designs.6,28,34,86 It has been reported that M2e-specific antibodies induced by M2e targeting
vaccines protect hosts by improving the survival rates, reducing lung virus titers or body weight
loss against heterosubtypic influenza A virus infection.18,61,68,87 However, the levels of cross
protection by M2e antibody itself are not sufficient, allowing moderate pathological symptoms.5
Epidemiologic studies indicated that anti-NA immunity and NA inhibitors prevent severe
disease or death by influenza viral infection.14 NA targeting antibodies do not have viral
neutralizing activity, providing infection-permissive protection.15 Studies have demonstrated that
NA immunity induces a broad spectrum of cross protection within the same subtype.16,17

69

Nonetheless, contribution of NA antibodies to cross protection is not well understood yet in
comparison with other viral surface antigens.
In the chapter 1, we investigated how NA immune responses contribute to cross protection by
comparing with those induced by tandem repeat M2e virus-like particle (M2e5x VLP) and
inactivated split virus (as HA) vaccines. NA antibodies were found to be more effective in
conferring heterologous cross-protection than strain-specific HA antibodies. The contribution of
NA immunity to protection appeared to be limited when compared to M2e immunity. Also, the
roles Fc receptors and complement protein C3 in mediating protection by NA antibodies were
investigated in mutant mouse models. Protective efficacy by NA-specific antibodies was lower in
Fc receptor deficient mice but comparable in complement C3 deficient mice compared to that in
the wild type mice. Thus, we concluded that Fc receptor plays a role in passively administered NA
antibody-mediated protection but C3 is not required (Figure 6.1).

6.3

The role of the genetic background of hosts in the cross protective immunity
Previously, it has been reported that virus-like particle (VLP) vaccines presenting heterologous

tandem repeat M2e (M2e5x VLP) were effective in inducing cross protection against different
subtypes of influenza viruses in the absence of adjuvants.34 Most of previous M2e-based vaccine
studies have been carried out in BALB/c mice known to be a high responder.65,71 No IgG antibodies
and T cell responses specific for M2e were induced in C57BL/6 mice that were primed with M2
DNA and boosted with M2 recombinant adenovirus.71 It is known that M2e5x VLP raises IgG
antibodies but provides low efficacy of cross protection in C57BL/6 mice without adjuvants.44
Vaccines should be effective in genetically diverse populations. In the chapter 2, to compare
different influenza vaccine platforms, we first determined the induction of IgG isotype antibodies
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and efficacy of protection in BALB/c and C57BL/6 mice after vaccination with M2e5x VLP, H5
VLP containing H5 subtype HA, or whole inactivated H3N2 virus (H3N2i). Overall, BALB/c and
C57BL/6 mice developed different patterns of IgG antibody responses depending on antigen types
and vaccine platforms. Especially, M2e-specific IgG antibody levels were significantly higher in
BALB/c than C57BL/6 mice, suggesting higher strain dependency of M2e immunity compared to
HA based vaccines. In addition, we found that both CD4+ and CD8+ T cells have important roles
in M2e immunity and BALB/c mice induce higher levels of M2e-specific T cell responses than
C57BL/6 mice (Figure 6.1).
As a model of pandemic in the future, the impact of immunization with different vaccine
platforms was analyzed after the primary challenge which was followed by the secondary
challenge. We found that BALB/c mice develop stronger secondary heterosubtypic immunity
against an antigenically different virus than C57BL/6 mice.

6.4

The cross-protection mechanism of the M2e based vaccine
Possibility of M2 as a cross protective vaccine candidate is based on the observation that

passive transfer of an anti-M2 monoclonal antibody into mice significantly reduces influenza virus
replication in the lung.18 Since M2-specific antibodies do not have virus neutralizing activity, antiM2 antibody-mediated immune protection has been considered to be connected with antibodydependent cell cytotoxicity (ADCC) or complement-mediated lysis.35-38 Innate immune cells such
as macrophages, dendritic cells, neutrophils, and NK cells lead to lyse antibody-bound infected
cells via interaction between Fc receptors (FcR) on their surface and antigens on the infected
cells.13,39,40 Based on these findings, FcR-mediated ADCC can be a possible mechanism of the
M2e immunity. The role of NK cell-mediated response is still controversial in M2e immunity. It

71

has been reported that NK cell-mediated ADCC is important in M2e immunity.35 However, an
arguing study showed NK cell independency in the protection by anti-M2e antibodies.86
Complement-mediated cell lysis is also a key mechanism for virus elimination.41,42 In the case of
M2e-mediated immunity, it is still controversial whether complement system is required for
protection.35,38 In addition, several studies have shown that M2e-specific T cells play a role in
enhancing cross protection against influenza infection.28,43,44
In the chapter 3, we investigated the possible roles of C3 in inducing immune responses and
protection after live influenza virus infection or immunization with M2e5x VLP or H5 HA VLP
vaccines. C3 was found to play an important role in inducing immune responses to live virus
infection or VLP vaccination (Figure 6.1). Moreover, we demonstrated a detailed protection
mechanism of M2e immunity, suggesting the role of the complement system in developing both
humoral and cellular immune responses by M2e vaccination (Figure 6.1). C3 was also found to
play a critical role for non-neutralizing immune-mediated protection by M2e5x VLP but not for
neutralizing immune-mediated protection by H5 HA VLP (Figure 6.1).
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Figure 6.1 Protection mechanisms of influenza vaccines upon different target antigens.
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